Table 1 Demographic and clinical characteristics of patients with SSc and healthy controls

N

25

49

32

17

Female, N (%)

21(84)

35 (71)

0.4^a

21 (66)

14 (82)

0.37^a

Age (years), mean (SD;IQR)

46(12;37-54)

52 (14; 46–62)

0.09^b

49 (14; 43–58)

56 (13; 52–63)

0.08^b

White, N (%)

14(56)

32 (65)

0.6^a

19 (59)

13 (76)

0.38^a

mRSS, mean (SD;IQR)

N/A

14 (11; 4.8–23)

N/A

18 (10; 9–26)

6.5 (6.1;3–6)

0.0001^b

Disease duration (years), mean (SD;IQR)

N/A

7.8 (4.9;3.9–12)

N/A

6.3 (3.7;3.3–8)

10 (5.8; 5–15)

0.02^b

Interstitial lung disease, N (%)

N/A

19 (40)

N/A

17 (57)

2 (12)

0.007^a

Immunosuppressive agent, N (%)

N/A

14 (29)

N/A

10 (31)

4 (24)

0.81^a

Anti-centromere Ab, N (%)

N/A

7 (14)

N/A

1 (3.1)

6 (35)

0.008^a

Anti-topoisomerase Ab, N (%)

N/A

13 (27)

N/A

10 (31)

3 (18)

0.49^a

RNA polymerase Ab, N (%)

N/A

12 (24)

N/A

11 (34)

1 (5.9)

0.06^a

Ribonucleoprotein Ab, N (%)

N/A

3 (6.1)

N/A

2 (6.2)

1 (5.9)

1.0^a